Phase 1 study of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Trial Profile

Phase 1 study of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Nalmefene (Primary)
  • Indications Opioid abuse
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Feb 2018 New trial record
    • 12 Feb 2018 According to Opiant Pharmaceuticals media release, positive data is published. and provided an update on a meeting held February 8, 2018 with the U.S. Food and Drug Administration (FDA) regarding its planned development program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top